It received the FDA approval in combination with an aromatase inhibitor letrozole [51] as a first-line treatment in post-menopausal women with hormone receptor positive, human epidermal growth factor receptor-2 negative (HR+/HER2−) advanced (metastatic) breast cancer. This evidence concerns the gene ERBB2 and breast cancer.